Cargando…
Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score(®) Test in Node-Negative Early Breast Cancer
BACKGROUND: The 21-gene assay (the Oncotype DX Breast Recurrence Score(®) test) is a validated multigene assay which produces the Recurrence Score(®) result (RS) to inform decisions on the use of adjuvant chemotherapy in human epidermal growth factor receptor 2-negative (HER2-), hormone receptor pos...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505370/ https://www.ncbi.nlm.nih.gov/pubmed/36157054 http://dx.doi.org/10.2147/CEOR.S360049 |